POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (6.14.2021, 10:56am CEST, WHO):   U.S. 11,678    India 80,834    Brazil 78,700    France 3,604    Turkey 6,076    Russia 14,723    The United Kingdom 7,550    Italy 1,722    Argentina 18,057    Columbia 29,998    Germany 1,489    Iran 8,195    Mexico 3,649    Peru 3,003    Indonesia 9,868    South Africa 9,319    The Netherlands 1,265    Chile 7,481    Canada 1,290    Philippines 7,302    Iraq 3,952    Pakistan 1,239    Bangladesh 2,436    Japan 1,409    Malaysia 5,304    Nepal 1,649    United Arab Emirates 1,969    Saudi Arabia 1,017    Ecuador 1,813    Bolivia 2,056    Paraguay 1,963    Tunisia 1,861    Uruguay 2,986    Kuwait 1,512    Guatemala 2,395    Venezuela 1,489    Honduras 1,379    Oman 1,482    Sri Lanka 2,361    Thailand 2,804    Cuba 1,470    Zambia 2,358    Afghanistan 1,597    Mongolia 2,188    Namibia 1,399    Uganda 1,735    China 198    Singapore 13    New Zealand 1    Australia 11    South Korea 399   

Low-cost blood test could be key weapon against No. 4 cancer killer in U.S.

Staff Writer |
A new, low-cost blood test may be an effective way to detect pancreatic cancer early, a research team says.

Article continues below

The nation's No. 3 cancer killer, pancreatic cancer often goes undiagnosed until it is too far along to remove.

Current screening techniques typically catch it only "after it causes pronounced symptoms, when it has advanced far enough to be lethal," said study author Kenneth Zaret, director of the University of Pennsylvania's Institute for Regenerative Medicine.

Sometimes it's found during a body scan for another health issue. But such scans are too costly for routine screening, even for people with a high risk of pancreatic cancer, he said. That includes parents, siblings or children of people who have had pancreatic cancer; those with some gene mutations; and people over 50 who suddenly develop diabetes.

"A low-cost, noninvasive test, such as we have developed, could be useful for routine screening of individuals who are at high risk for pancreatic cancer," Zaret said.

Current screening focuses on shifting levels of tell-tale blood proteins, according to the American Cancer Society. But such tests are considered unreliable, and the ACS does not recommend routine screening for those who are not known to be at high-risk.

Zaret's team set out to find new, reliable markers for early stage pancreatic cancer.

To begin, the researchers genetically "reprogrammed" late-stage cancer cells to mimic cells at the early stage of cancer. They identified several new cellular "biomarkers" triggered by the onset of disease.

Then, the team did three rounds of testing in roughly 700 blood samples. Samples were drawn from pancreatic cancer patients (at different stages of disease) and from healthy people.

Researchers were able to diagnose early stage pancreatic cancer - with 98 percent accuracy - by screening for two of the new biomarkers they identified, called THBS2 and CA19-9.

Zaret expressed confidence in the results so far. He said the screening tool would, at minimum, appear to be "useful" for testing people known to be at high risk for pancreatic cancer. He added it might lead to development of new, early stage treatments.

"It is noteworthy that the biomarker panel employs existing technology that is routinely available in diagnostic clinics around the country, facilitating the dissemination of the test, with further validation," Zaret said.

But that validation will require a much larger study to find out whether the new approach holds up as a screening tool for the general population.

What to read next

Chilean engineer develops early cancer detection system
DNA Mapping may lead to personalized cancer treatment
Doctors in South Korea successfully detect cancer cells in blood